New FDA rules change drug policy for rescue units
Fire and rescue departments across Virginia, though, are having to make changes to the way they store and transport those drugs — and it might change the way you're billed for that emergency call.
It's due to the Drug Supply Chain Security Act that takes effect next month, and while it's a big change for fire departments, it also gives them a bit more freedom when it comes to treating their patients.
'The EMS agencies are now becoming the pharmacy said Dr. Carl Wentzel, operational medical director for Suffolk Fire & Rescue, 'where before, our pre-hospital drug use supply came from the local area hospitals.'
Up until now, EMS agencies operated on a box-for-box exchange after every call.
'Meaning, if I use this box and if I only use aspirin or only used epinephrine, I would take this whole box, take it to the pharmacy, [and] they would then return me a completely new box,' said Suffolk Fire & Rescue Capt. Jeff Matthews.
But there was no 'chain of custody,' meaning the pharmacies didn't know which medications went to which patient. Now, EMS teams are in charge of that. It's partly in response to the opioid crisis.
'They're appropriate medications when given in the correct way,' Wentzel said, 'but it's putting tighter control on management of those types of medications.'
Wentzel said it will help them serve folks in the community better — giving them the freedom to stock up on drugs they use most often on calls and better adapt to changes in care instead of waiting on another agency to approve new protocol.
Many states have been doing this for a while, but now, the Food and Drug Administration is mandating all states be on the same page. It took Suffolk Fire & Rescue six months and $450,000 to build a makeshift pharmacy to be in compliance.
But with this new process, will the patient end up paying more?
'What we want to do is study it for one year and see what the increased cost is to manage and supply our pharmacy and our IV boxes,' said Suffolk Fire Chief Mike Barakey. 'And when that occurs, we'll have real data to see what can be worked on in our EMS billing company to figure out what we need to do to offset that increase.'
That way, they can figure out what the department can absorb and what costs they might have to pass on to the patient.
Wentzel said Suffolk has been a leader when it comes to this new process, and several agencies have come to analyze their setup to get an idea for their model.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
4 hours ago
- UPI
FDA approves use of animal drugs to treat New World Screwworm
The Food and Drug Administration is seeking to prevent possible infestations of the New World Screwworm by authorizing the use of animal drugs. File Photo by Juan Manuel Blanco/EPA-EFE Aug. 20 (UPI) -- The Food and Drug Administration has authorized emergency use of animal drugs to treat and prevent infestations of the New World Screwworm, which poses an emerging threat to U.S. livestock and food security. The parasite infests warm-blooded animals and in rare cases humans, causing tissue damage and occasionally death. Though eradicated in both North and Central America a decades ago, the screwworm has progressed north since 2022 and is nearing the U.S. southern border. The U.S. Department of Health and Human Services said it issued a declaration on Tuesday allowing the FDA to issue emergency use authorizations for animal drugs to prevent infestations. "Today, we are taking decisive action to safeguard the nation's food supply from this emerging threat," HHS Secretary Robert F. Kennedy Jr. said in a statement. "This authorization equips FDA to act quickly, limit the spread of New World Screwworm and protect America's livestock." Endemic to Cuba, Haiti, Dominican Republic and the countries of South America, the New World Screwworm strikingly resembles a fly, but when in its larval stage it burrows into the flies of a living animals, such as livestock, the U.S. Department of Agriculture said. The United States has worked with Panama for decades to prevent the parasite's northward expansion, according to the USDA, which resulted in the eradication of the insect from the United States in 1966. There are no FDA-approved drugs for NWS, but through an Emergency Use Authorization, the FDA can permit the use of certain animal drug products that have been approved for other purposes or are available in other countries. "This emergency use authorization is another tool we can use in the fight against New World Screwworm," Agriculture Secretary Brooke Rollins said. "Our cattle ranchers and livestock producers are relying on the Trump administration to defend their livelihoods. Stopping this pest is a national security priority and we are linking arms across President [Donald] Trump's Cabinet to defend our borders and push back this threat."
CNBC
9 hours ago
- CNBC
FDA approves first-ever glucose monitoring system for weight loss from Signos
The Food and Drug Administration on Wednesday approved the first-ever glucose monitoring system specifically for weight loss from the startup Signos, establishing a new option for Americans to manage their weight. Current treatment options for losing weight – popular drugs like GLP-1s and surgical interventions – are typically limited to patients with obesity or a certain BMI. Obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound can also be difficult to access due to their high costs, limited U.S. insurance coverage and constrained supply. But now, any patient can purchase a Signos membership to access its system. It uses an AI platform and an off-the-shelf continuous glucose monitor, or CGM, from Dexcom to offer personalized, real-time data and lifestyle recommendations for weight management. "There is now a solution that everybody can use to help on the weight loss journey, and you don't have to be a certain number of pounds to use it. It's available for the average American who needs it," said Sharam Fouladgar-Mercer, Signos' co-founder and CEO, in an interview on Tuesday ahead of the approval. "The average person might have five pounds to lose, or others might have 100 pounds to lose. We are here to help them at any point in that journey." The obesity epidemic costs the U.S. health-care system more than $170 billion a year, according to Centers for Disease Control and Prevention data. Almost 74% of Americans are overweight or obese, government data says. Signos hopes it can make a "real big dent in that curve for the betterment of many of us," Fouladgar-Mercer said. Customers who sign up for Signos can choose a three-month or six-month plan, which currently costs $139 and $129, respectively. The company will ship out all of the CGMs a patient needs for the number of months in the plan they choose. Insurers currently don't cover the system for weight management, but the plans are a fraction of the roughly $1,000 monthly price of GLP-1s in the U.S. Signos is working with health insurance companies and employers to get coverage for the system, the company said in a statement to CNBC. Signos said it expects "this to evolve quickly as interest for tackling weight continued to expand." The Signos system can be used in combination with GLP-1s or bariatric surgery, said Fouladgar-Mercer. He said patients can also use the system after getting off a GLP-1 to maintain their weight loss. CGMs are small sensors worn on the upper arm that track glucose levels, mainly for people with diabetes. That data is wirelessly sent to Signos' app, which also allows patients to log their food intake and exercise levels, among other information that the AI platform uses to make recommendations. Apart from helping people lose pounds, the system aims to help users understand how their bodies respond to specific foods and exercise patterns and make the right behavioral changes to manage and maintain their weight in the long term. Signos did not share how many patients are currently using its glucose monitoring system, but Fouladgar-Mercer said tens of thousands of people have already tried it over time. He said Signos has scaled up its CGM inventory and software capacity to "handle a pretty massive scale" following the approval.
American Military News
15 hours ago
- American Military News
Gov't agency exposed for allowing drugs from dangerous foreign factories into the US: Report
A new report claims that the U.S. Food and Drug Administration secretly allowed substandard foreign factories with dangerous manufacturing issues to ship hundreds of medications to the United States despite being officially banned by the agency. In June, ProPublica reported that a group of individuals inside the Food and Drug Administration exempted drugs shipped to the U.S. from foreign factories despite the agency banning imports from certain factories due to contamination and other issues. The outlet noted that pills and other medications exempted from the bans were distributed to Americans and claimed that the agency did not regularly test the drugs for quality issues or track the medications to determine whether the medications were causing harm. According to ProPublica, Janet Woodcock, a former Food and Drug Administration employee, told the outlet, 'We felt we didn't have to make it a public thing.' READ MORE: Experimental vaccine may prevent recurrence of cancer In a new report, ProPublica claimed that the Food and Drug Administration did not adequately monitor various reports filed by medical providers and other individuals who warned that some drugs had a bad odor, residue, or abnormal taste. The outlet claimed that the government agency also did not adequately monitor reports of patients experiencing abnormal health issues potentially related to certain medications. According to ProPublica, the Food and Drug Administration largely withheld the information regarding the medication import ban exemptions from the American public and has not shared a list of medications that the U.S. government allowed into the country from foreign factories banned by the agency. However, ProPublica released a list of the drugs and ingredients that the outlet determined were exempted from import bans since 2013. The list also reveals the manufacturing companies responsible for the production of the medications. ProPublica reported that the news outlet found that the Food and Drug Administration exempted over 150 medications and ingredients from import bans. While the majority of the exempted products came from India, ProPublica reported that a Chinese factory and a Hungarian factory were also exempted by the federal agency.
